Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Shaw

Showing results (1021-1030 of 1,055) with videos related to

Pageof 106
Sort By:
Journal of Medicinal Chemistry|October 13, 2007
Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974)Daniel V Paone, Anthony W Shaw, Diem N Nguyen, et al.
Human Molecular Genetics|January 25, 2024
Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progressionChao-Jen Wong, Seth D Friedman, Lauren Snider, et al.
Journal of Medicinal Chemistry|June 27, 2003
Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agentsS Jane deSolms, Terrence M Ciccarone, Suzanne C MacTough, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial designChao-Jen Wong, Seth D Friedman, Lauren Snider, et al.
Stroke|December 18, 2019
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in ChildrenCatherine Amlie-Lefond, Dennis W W Shaw, Andrew Cooper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2011
Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic responseD B Jernigan, S L Lindstrom, J R Johnson, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|April 26, 2024
Validation of the first-trimester machine learning model for predicting pre-eclampsia in an Asian populationLong Nguyen-Hoang, Daljit S Sahota, Ritsuko K Pooh, et al.
Journal of Neurosurgery. Pediatrics|November 4, 2017
Corticospinal tract atrophy and motor fMRI predict motor preservation after functional cerebral hemispherectomyAnthony C Wang, George M Ibrahim, Andrew V Poliakov, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Pageof 106

Showing results (1021-1030 of 1,055) with videos related to

Sort By:
Pageof 106
Journal of Medicinal Chemistry|October 13, 2007
Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974)Daniel V Paone, Anthony W Shaw, Diem N Nguyen, et al.
Human Molecular Genetics|January 25, 2024
Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progressionChao-Jen Wong, Seth D Friedman, Lauren Snider, et al.
Journal of Medicinal Chemistry|June 27, 2003
Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agentsS Jane deSolms, Terrence M Ciccarone, Suzanne C MacTough, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial designChao-Jen Wong, Seth D Friedman, Lauren Snider, et al.
Stroke|December 18, 2019
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in ChildrenCatherine Amlie-Lefond, Dennis W W Shaw, Andrew Cooper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2011
Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic responseD B Jernigan, S L Lindstrom, J R Johnson, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|April 26, 2024
Validation of the first-trimester machine learning model for predicting pre-eclampsia in an Asian populationLong Nguyen-Hoang, Daljit S Sahota, Ritsuko K Pooh, et al.
Journal of Neurosurgery. Pediatrics|November 4, 2017
Corticospinal tract atrophy and motor fMRI predict motor preservation after functional cerebral hemispherectomyAnthony C Wang, George M Ibrahim, Andrew V Poliakov, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Pageof 106